100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94

Key Takeaways

• 100% tariffs target drugs from non‑trade‑deal nations
• Lilly’s oral GLP‑1 approved in 50 days, fast
• Centessa deal values at $6.3 B upfront, plus milestones
• Biogen pays $5.6 B for Apellis, adds nephrology assets
• M&A volume hits $12 B, indicating robust market confidence

Summary

The White House announced 100% tariffs on branded drug imports from countries lacking trade agreements, prompting biotech firms to reassess supply‑chain and pricing strategies. Eli Lilly secured a rapid FDA approval for Foundayo, the first oral small‑molecule GLP‑1 for chronic weight management, and simultaneously announced a $6.3 billion cash acquisition of Centessa. Biogen agreed to buy Apellis for $5.6 billion, adding two complement‑pathway drugs and a nephrology platform. The week’s deal flow topped $12 billion, underscoring continued appetite for large‑scale M&A despite policy uncertainty.

Pulse Analysis

The administration’s 100% tariff order on selected branded pharmaceuticals and active‑ingredient imports is more than a customs cost increase; it forces companies to re‑engineer supply chains, renegotiate contract manufacturing, and embed policy risk into margin forecasts. Early‑stage mitigation includes diversifying API sources, reshoring production, and building pricing buffers to absorb potential payer push‑back. Investors are now scrutinizing each product’s exposure to politically sensitive markets rather than treating the sector as a monolith.

Lilly’s approval of orforglipron (Foundayo) marks the first oral GLP‑1 therapy that can be taken without food or water timing constraints, a clear differentiator in a market dominated by injectable options from Novo Nordisk. The rapid 50‑day FDA clearance, enabled by the National Priority Voucher, showcases Lilly’s regulatory agility and positions the company to capture patients seeking convenience and improved adherence. Competitive dynamics will shift toward real‑world persistence data and payer negotiations, as both firms vie for channel share across adherence, cost, and outcomes.

Beyond tariffs and product launches, the $12 billion M&A surge—highlighted by Lilly’s Centessa purchase and Biogen’s Apellis acquisition—demonstrates that large pharma remains willing to deploy capital when commercial visibility is clear. Deals like Merck’s $838 million milestone‑based antibody collaboration reflect a preference for risk‑sharing structures over hefty upfront fees. This environment rewards assets with near‑term revenue streams and robust pipeline synergies, while marginalizing companies that cannot secure data credibility or clear commercialization pathways. The confluence of policy, innovation, and strategic buying is reshaping the biotech landscape for the coming year.